April 16th 2024
At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Better Survival for Necitumumab With Chemotherapy in Metastatic Squamous NSCLC
September 11th 2015For patients who have metastatic squamous non-small cell lung cancer (NSCLC) whose tumors were positive for EGFR copy number, as determined by the FISH analysis, survival tended to be better with the addition of necitumumab to their conventional chemotherapy.
Read More
Bevacizumab With Chemotherapy Doublet Improves Survival for Patients With Mesothelioma
September 11th 2015By adding bevacizumab (Avastin) to a standard chemotherapy doublet, the risk of death is reduced by 24%, with the risk of disease reducing by 39%, in patients who have malignant pleural mesothelioma (MPM).
Read More
Alectinib Granted Priority Review by the FDA in NSCLC
September 9th 2015The FDA recently granted alectinib a priority review designation for patients who have ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) and progressed or are intolerant to crizotinib (Xalkori).
Read More
Treatment Strategies With NTRK Gene Rearrangements Emerge in Lung and Other Solid Tumors
September 4th 2015The standard of care for lung cancers has been dramatically transformed by the growing availability of molecular diagnostics and genetic testing, and by targeted therapies that specifically inhibit a number of well-established oncogenic drivers.
Read More
New York Lung Cancer Conference to Prominently Feature Immunotherapy and Targeted Therapies
August 10th 2015On November 7, 2015, some of the leading experts in oncology, together with other oncology healthcare professionals involved in the treatment and management of patients with lung cancer, will gather in Manhattan for the 10th Annual New York Lung Cancer Symposium®.
Read More
Translational Advances Deliver Precision Medicine to NSCLC
August 5th 2015Precision medicine with TKIs and immunotherapies is revolutionizing the treatment of patients with NSCLC. Paul A. Bunn, Jr, MD, head of the Division of Medical Oncology at the University of Colorado, discussed the current translational advances with these agents in a discussion held at this year’s International Lung Cancer Congress.
Read More
New Trial Designs Hope to Improve the Discovery of Biomarkers in NSCLC
August 5th 2015Clinical trial designs are experiencing a huge transformation geared toward the discovery and confirmation of new predictive biomarkers for patients who have non-small cell lung cancer (NSCLC), as well as other types of solid tumors.
Read More
Radiation Therapy Dose for the Treatment of Patients With Lung Cancer
August 4th 2015Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.
Read More
Rociletinib NDA Completed by Clovis Oncology for EGFR T790M-positive NSCLC
August 4th 2015A new drug application (NDA) was recently submitted for rociletinib (CO-1686) as a treatment for patients who have EGFR T790M-positive metastatic non-small cell lung cancer (NSCLC) following previous administration of an EGFR TKI.
Read More
Combinations of Checkpoint Inhibitors Under Investigation in NSCLC
August 4th 2015After a successful demonstration as single-agents, clinical trials are currently assessing PD-1 and PD-L1 inhibitors, combined with chemotherapy, targeted therapies, and radiation therapy, in an attempt to further improve outcomes for patients who have non-small cell lung cancer (NSCLC).
Read More
SBRT in Surgery for Patients With Early NSCLC
August 3rd 2015Roy Decker, MD, PhD, associate professor of therapeutic radiology, assistant professor of surgery (Otolaryngology), Clinical Research Program Leader, Therapeutic Radiology, Yale University, discusses stereotactic body radiation therapy (SBRT) in surgery for patients with early non-small cell lung cancer (NSCLC).
Read More
Clinical Trials in EGFR-Mutant NSCLC Hasten Precision Medicine Initiatives
July 31st 2015In addition to late patient presentation, the high mortality rate in lung cancer can be largely attributed to the complex nature of the disease and a very high rate of heterogeneity in the causative molecular abnormalities.
Read More
Immunotherapy Versus Targeted Therapy - Which Has Greater Impact in NSCLC?
July 30th 2015Immunotherapies (immune checkpoint inhibitors) and targeted therapies (tyrosine kinase inhibitors [TKIs] that target specific mutations in one or more oncogenic drivers) represent two of the most researched types of therapy under investigation for the treatment of non-small cell lung cancer (NSCLC).
Read More